论文部分内容阅读
Immune cell-based therapies provide promising strategies for the treatment of hematologic malignancies.CAR-T immunotherapy, referring to T cells engineered to express chimeric antigen receptors (CARs), which targeted CD19-expressing B-cell-derived tumors, has demonstrated remarkable and durable clinical responses in patients with hematological cancers [1].However, CAR-T immunotherapy has to date been comparatively less effective for solid tumors, primarily due to their limited penetration into solid tumors [2].A recent study reported that high endothelial venules (HEVs) restricts the recruitment of cytotoxic effector T lymphocytes through a physical barrier in numerous types of human tumors [3].